文献速递浆细胞疾病造血干细胞移植与细胞治疗

多发性骨髓瘤的自体移植、巩固与维持治疗:BMT CTN 0702 试验结果

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
PubMed 文献 · J Clin Oncol · 2019-01-17

这项前瞻性随机III期研究比较了单次自体造血干细胞移植(AHCT)后来那度胺维持、串联AHCT后维持、以及AHCT后4周期来那度胺+硼替佐米+地塞米松(RVD)巩固后维持三种策略,主要终点为38个月无进展生存(PFS)。结果显示三种策略的38个月PFS率、总生存(OS)率和1年完全缓解率均无显著差异,毒性谱和第二原发恶性肿瘤发生率相似。结论认为第二次AHCT或RVD巩固并未改善PFS或OS,单次AHCT联合来那度胺维持应继续作为该人群的标准方案。

要点

  • 38个月PFS率:串联AHCT+来那度胺组58.5%,AHCT+RVD+来那度胺组57.8%,单次AHCT+来那度胺组53.9%。
  • 总生存率三组分别为81.8%、85.4%和83.7%,1年完全缓解率分别为50.5%、58.4%和47.1%。
  • 第二次AHCT或RVD巩固作为AHCT后干预未改善PFS或OS;单次AHCT联合来那度胺维持应继续作为标准方案。

核心结论

  • 第二次AHCT或RVD巩固作为移植后干预用于适合移植的多发性骨髓瘤患者的 upfront 治疗,未改善PFS或OS。
  • 单次AHCT联合来那度胺维持应继续作为该人群的标准方案。

研究设计与样本

  • 前瞻性、随机、III期研究,纳入年龄≤70岁、开始治疗后12个月内且无进展的症状性多发性骨髓瘤患者。
  • 患者随机分配至串联AHCT+来那度胺组(n=247)、AHCT+RVD+来那度胺组(n=254)或单次AHCT+来那度胺组(n=257),均后续来那度胺维持至疾病进展。
  • 主要终点为38个月PFS。

主要发现

  • 研究人群中位年龄56岁(范围20-70岁),24%为高危多发性骨髓瘤,73%初始治疗为三药方案,入组时18%达完全缓解。
  • 38个月PFS率:串联AHCT+来那度胺组58.5%(95%CI 51.7%-64.6%),AHCT+RVD+来那度胺组57.8%(95%CI 51.4%-63.7%),单次AHCT+来那度胺组53.9%(95%CI 47.4%-60%)。
  • 总生存率:串联AHCT+来那度胺组81.8%(95%CI 76.2%-86.2%),AHCT+RVD+来那度胺组85.4%(95%CI 80.4%-89.3%),单次AHCT+来那度胺组83.7%(95%CI 78.4%-87.8%)。
  • 1年完全缓解率:串联AHCT+来那度胺组50.5%(n=192),AHCT+RVD+来那度胺组58.4%(n=209),单次AHCT+来那度胺组47.1%(n=208)。
  • 各治疗组毒性谱和第二原发恶性肿瘤发生情况相似。

临床怎么用

  • 单次AHCT联合来那度胺维持应继续作为适合移植的多发性骨髓瘤患者的标准方案。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Single-cycle melphalan 200 mg/m2 and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a prospective, randomized, phase III study to test additional interventions to improve PFS by comparing AHCT, tandem AHCT (AHCT/AHCT), and AHCT and four subsequent cycles of len, bortezomib, and dexamethasone (RVD; AHCT + RVD), all followed by len until disease progression. PATIENTS AND METHODS: Patients with symptomatic MM within 12 months from starting therapy and without progression who were age 70 years or younger were randomly assigned to AHCT/AHCT + len (n = 247), AHCT + RVD + len (n = 254), or AHCT + len (n = 257). The primary end point was 38-month PFS. RESULTS: The study population had a median age of 56 years (range, 20 to 70 years); 24% of patients had high-risk MM, 73% had a triple-drug regimen as initial therapy, and 18% were in complete response at enrollment. The 38-month PFS rate was 58.5% (95% CI, 51.7% to 64.6%) for AHCT/AHCT + len, 57.8% (95% CI, 51.4% to 63.7%) for AHCT + RVD + len, and 53.9% (95% CI, 47.4% to 60%) for AHCT + len. For AHCT/AHCT + len, AHCT + RVD + len, and AHCT + len, the OS rates were 81.8% (95% CI, 76.2% to 86.2%), 85.4% (95% CI, 80.4% to 89.3%), and 83.7% (95% CI, 78.4% to 87.8%), respectively, and the complete response rates at 1 year were 50.5% (n = 192), 58.4% (n = 209), and 47.1% (n = 208), respectively. Toxicity profiles and development of second primary malignancies were similar across treatment arms. CONCLUSION: Second AHCT or RVD consolidation as post-AHCT interventions for the up-front treatment of transplantation-eligible patients with MM did not improve PFS or OS. Single AHCT and len should remain as the standard approach for this population.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol. 2019. PMID: 30653422. doi:10.1200/JCO.18.00685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。